Celldex Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage is a free Environmental, Social and Governance analysis for Celldex Therapeutics Inc. The report of Celldex Therapeutics Inc is prepared by All Street Sevva using proprietary AI. This webpage includes a Q&A section about Celldex Therapeutics Inc.
Celldex Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 5.3, social score of 2.3 and governance score of 8.0.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 658 | Transchem Ltd | 5.3 | High |
| 658 | Zenith Healthcare Ltd | 5.3 | High |
| 687 | Celldex Therapeutics Inc | 5.2 | High |
| 687 | Cardiol Therapeutics Inc | 5.2 | High |
| 687 | Cell Source Inc | 5.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Celldex Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Celldex Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Celldex Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Celldex Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Celldex Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Celldex Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Celldex Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Celldex Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Celldex Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Celldex Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Celldex Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Celldex Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Celldex Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Celldex Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Celldex Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Celldex Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Celldex Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Celldex Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.